Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer

European Journal of Surgical Oncology

Volumn 44, Issue 7, 2018, Pages 975-982

  Furuki, Hiroyasu ^a   Yamada, Takeshi ^a   Takahashi, Goro ^a   Iwai, Takuma ^a   Koizumi, Michihiro ^a   Shinji, Seiichi ^a   Yokoyama, Yasuyuki ^a   Takeda, Kohki ^a   Taniai, Nobuhiko ^a   Uchida, Eiji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Colon cancer; Gene mutation; Genomic evolution; Liquid biopsy; Next generation sequencing

Indexed keywords

DNA; APC PROTEIN; APC PROTEIN, HUMAN; B RAF KINASE; BRAF PROTEIN, HUMAN; F BOX/WD REPEAT CONTAINING PROTEIN 7; FBXW7 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CARCINOMA; COLORECTAL TUMOR; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL IMAGING; DNA EXTRACTION; FEMALE; GENE MUTATION; HUMAN; LIQUID BIOPSY; LIVER METASTASIS; LIVER TUMOR; MALE; METASTATIC COLORECTAL CANCER; NEXT GENERATION SEQUENCING; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CANCER STAGING; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LIVER RESECTION; LYMPH NODE; METASTASIS; METASTASIS RESECTION; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; SECONDARY; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; AGED, 80 AND OVER; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLORECTAL NEOPLASMS; F-BOX-WD REPEAT-CONTAINING PROTEIN 7; FEMALE; GTP PHOSPHOHYDROLASES; HEPATECTOMY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIQUID BIOPSY; LIVER NEOPLASMS; LYMPH NODES; MALE; MEMBRANE PROTEINS; METASTASECTOMY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85041965160     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2018.01.224     Document Type: Article

References (31)

1. Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 37 (2017), 785–792.
2. Knijn, N., Mekenkamp, L.J., Klomp, M., Vink-Borger, M.E., Tol, J., Teerenstra, S., et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104 (2011), 1020–1026.
3. Baas, J.M., Krens, L.L., Guchelaar, H.J., Morreau, H., Gelderblom, H., Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 16 (2011), 1239–1249.
4. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
5. McGranahan, N., Favero, F., de Bruin, E.C., Birkbak, N.J., Szallasi, Z., Swanton, C., Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med, 7, 2015 283ra254.
6. Yamada, T., Iwai, T., Takahashi, G., Kan, H., Koizumi, M., Matsuda, A., et al. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. Cancer Sci 107 (2016), 936–943.
7. Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
8. Chan, K.C., Leung, S.F., Yeung, S.W., Chan, A.T., Lo, Y.M., Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res: Official J Am Assoc Cancer Res 14 (2008), 4141–4145.
9. Spindler, K.L., Pallisgaard, N., Vogelius, I., Jakobsen, A., Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res: Official J Am Assoc Cancer Res 18 (2012), 1177–1185.
10. Thierry, A.R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20 (2014), 430–435.
11. Chaudhuri, A.A., Binkley, M.S., Osmundson, E.C., Alizadeh, A.A., Diehn, M., Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 25 (2015), 305–312.
12. Mao, C., Wu, X.Y., Yang, Z.Y., Threapleton, D.E., Yuan, J.Q., Yu, Y.Y., et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep, 5, 2015, 8065.
13. Mostert, B., Jiang, Y., Sieuwerts, A.M., Wang, H., Bolt-de Vries, J., Biermann, K., et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 133 (2013), 130–141.
14. Park, J.H., Han, S.W., Oh, D.Y., Im, S.A., Jeong, S.Y., Park, K.J., et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68 (2011), 1045–1055.
15. Higasa, K., Miyake, N., Yoshimura, J., Okamura, K., Niihori, T., Saitsu, H., et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet 61 (2016), 547–553.
16. Ohira, T., Sakai, K., Matsubayashi, J., Kajiwara, N., Kakihana, M., Hagiwara, M., et al. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Cancer Sci 107 (2016), 1660–1666.
17. Shihab, H.A., Rogers, M.F., Gough, J., Mort, M., Cooper, D.N., Day, I.N., et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics (Oxford, England) 31 (2015), 1536–1543.
18. Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M., et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42 (2014), D980–985.
19. Genovese, G., Kahler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
20. Nystrand, C.F., Ghanima, W., Waage, A., Jonassen, C.M., JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR. Int J Lab Hematol, 2017, 10.1111/ijlh.12762 28.
21. Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30 (2012), 2956–2962.
22. Goswami, R.S., Patel, K.P., Singh, R.R., Meric-Bernstam, F., Kopetz, E.S., Subbiah, V., et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res: Official J Am Assoc Cancer Res 21 (2015), 2644–2651.
23. Kim, T.M., Jung, S.H., An, C.H., Lee, S.H., Baek, I.P., Kim, M.S., et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin Cancer Res: Official J Am Assoc Cancer Res 21 (2015), 4461–4472.
24. Yao, Y., Liu, J., Li, L., Yuan, Y., Nan, K., Wu, X., et al. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget 8 (2017), 2130–2140.
25. Sato, K.A., Hachiya, T., Iwaya, T., Kume, K., Matsuo, T., Kawasaki, K., et al. Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. PLoS One, 11, 2016, e0146275.
26. Jovelet, C., Ileana, E., Le Deley, M.C., Motte, N., Rosellini, S., Romero, A., et al. Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial. Clin Cancer Res: Official J Am Assoc Cancer Res 22 (2016), 2960–2968.
27. Thompson, J.C., Yee, S.S., Troxel, A.B., Savitch, S.L., Fan, R., Balli, D., et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res: Official J Am Assoc Cancer Res 22 (2016), 5772–5782.
28. Beije, N., Helmijr, J.C., Weerts, M.J., Beaufort, C.M., Wiggin, M., Marziali, A., et al. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. Mol Oncol, 2016, 10.1016/j.molonc.2016.10.001.
29. Kim, S.T., Lee, W.S., Lanman, R.B., Mortimer, S., Zill, O.A., Kim, K.M., et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget 6 (2015), 40360–40369.
30. Lebofsky, R., Decraene, C., Bernard, V., Kamal, M., Blin, A., Leroy, Q., et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9 (2015), 783–790.
31. Solassol, J., Ramos, J., Crapez, E., Saifi, M., Mange, A., Vianes, E., et al. KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci 12 (2011), 3191–3204.